AP2000001766A0 - Vitronectin receptor anatagonists. - Google Patents

Vitronectin receptor anatagonists.

Info

Publication number: AP2000001766A0
Authority: AP; ARIPO
Prior art keywords: vitronectin receptor; receptor anatagonists; anatagonists; 6alkyl; vitronectin
Prior art date: 1997-09-19

Application number

APAP/P/2000/001766A

Other languages

English (en)

Inventor

William Edward Bondinell

William E Miller

James Martin Samanen

Original Assignee

Smithkline Beecham Corp

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1997-09-19

Filing date

1998-09-18

Publication date

1998-09-18

1998-09-18 Application filed by Smithkline Beecham Corp filed Critical Smithkline Beecham Corp

1998-09-18 Publication of AP2000001766A0 publication Critical patent/AP2000001766A0/en

Links

102100022337 Integrin alpha-V Human genes 0.000 title abstract 2
108010048673 Vitronectin Receptors Proteins 0.000 title abstract 2
208000001132 Osteoporosis Diseases 0.000 abstract 1
150000001875 compounds Chemical class 0.000 abstract 1
125000001475 halogen functional group Chemical group 0.000 abstract 1
239000002464 receptor antagonist Substances 0.000 abstract 1
229940044551 receptor antagonist Drugs 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/73—Unsubstituted amino or imino radicals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D233/28—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/44—Nitrogen atoms not forming part of a nitro radical
- C07D233/48—Nitrogen atoms not forming part of a nitro radical with acyclic hydrocarbon or substituted acyclic hydrocarbon radicals, attached to said nitrogen atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/06—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D239/08—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms directly attached in position 2
- C07D239/12—Nitrogen atoms not forming part of a nitro radical
- C07D239/14—Nitrogen atoms not forming part of a nitro radical with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, attached to said nitrogen atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
- C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
- C07D263/58—Benzoxazoles; Hydrogenated benzoxazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/38—Nitrogen atoms
- C07D277/42—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D313/00—Heterocyclic compounds containing rings of more than six members having one oxygen atom as the only ring hetero atom
- C07D313/02—Seven-membered rings
- C07D313/06—Seven-membered rings condensed with carbocyclic rings or ring systems
- C07D313/10—Seven-membered rings condensed with carbocyclic rings or ring systems condensed with two six-membered rings
- C07D313/14—[b,f]-condensed
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Life Sciences & Earth Sciences (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Rheumatology (AREA)
Physical Education & Sports Medicine (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Orthopedic Medicine & Surgery (AREA)
Urology & Nephrology (AREA)
Vascular Medicine (AREA)
Pain & Pain Management (AREA)
Oncology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Thiazole And Isothizaole Compounds (AREA)
Other In-Based Heterocyclic Compounds (AREA)
Pyridine Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

APAP/P/2000/001766A 1997-09-19 1998-09-18 Vitronectin receptor anatagonists. AP2000001766A0 (en)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US5934297P	1997-09-19	1997-09-19
US6343897P	1997-10-29	1997-10-29
PCT/US1998/019466 WO1999015508A1 (fr)	1997-09-19	1998-09-18	Antagonistes du recepteur de la vitronectine

Publications (1)

Publication Number	Publication Date
AP2000001766A0 true AP2000001766A0 (en)	1998-09-18

Family

ID=26738652

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
APAP/P/2000/001766A AP2000001766A0 (en)	1997-09-19	1998-09-18	Vitronectin receptor anatagonists.

Country Status (26)

Country	Link
EP (1)	EP1025090A4 (fr)
JP (1)	JP2001517658A (fr)
KR (1)	KR20010024141A (fr)
CN (1)	CN1278250A (fr)
AP (1)	AP2000001766A0 (fr)
AR (1)	AR015446A1 (fr)
AU (1)	AU738433B2 (fr)
BG (1)	BG104314A (fr)
BR (1)	BR9812340A (fr)
CA (1)	CA2303487A1 (fr)
CO (1)	CO5011087A1 (fr)
DZ (1)	DZ2609A1 (fr)
EA (1)	EA200000336A1 (fr)
HU (1)	HUP0003641A3 (fr)
ID (1)	ID24162A (fr)
IL (1)	IL135028A0 (fr)
MA (1)	MA26547A1 (fr)
NO (1)	NO20001407D0 (fr)
NZ (1)	NZ503389A (fr)
OA (1)	OA11341A (fr)
PE (1)	PE122699A1 (fr)
PL (1)	PL339381A1 (fr)
SK (1)	SK4082000A3 (fr)
TR (1)	TR200000721T2 (fr)
TW (1)	TW513303B (fr)
WO (1)	WO1999015508A1 (fr)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CO4920232A1 (es) *	1997-01-08	2000-05-29	Smithkline Beecham Corp	Acidos aceticos dibenzo [a,d] cicloheptano con actividad antagonista del receptor de vitronectin
WO2000046215A1 (fr)	1999-02-03	2000-08-10	Merck & Co., Inc.	Derives de la benzazepine utilises comme antagonistes du recepteur alpha-v de l'integrine
DE19936780A1 (de)	1999-08-09	2001-02-15	Basf Ag	Neue Antagonisten von Integrinrezeptoren
EG24179A (en) *	1999-09-07	2008-09-28	Smithkline Beecham Corp	Vitronectin receptor antagonists
US6881736B1 (en)	1999-09-07	2005-04-19	Smithkline Beecham Corporation	Vitronectin receptor antagonists
US6514964B1 (en)	1999-09-27	2003-02-04	Amgen Inc.	Fused cycloheptane and fused azacycloheptane compounds and their methods of use
FR2806082B1 (fr) *	2000-03-07	2002-05-17	Adir	Nouveaux composes bicycliques antagonistes des recepteurs de la vitronectine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
EP1289959A1 (fr)	2000-06-15	2003-03-12	Pharmacia Corporation	Derives d'acide alkanoique dihydrostilbene utilises comme antagonistes de la vitronectine
AU3943502A (en) *	2000-10-24	2002-05-27	Merck & Co Inc	Dibenzoxazepine alpha v integrin receptor antagonist
WO2002085405A2 (fr)	2001-04-24	2002-10-31	Merck Patent Gmbh	POLYTHERAPIE A BASE D'AGENTS ANTIANGIOGENIQUES ET DE FACTEUR DE NECROSE TUMORALE TNF$g(a)
GB0215867D0 (en) *	2002-07-09	2002-08-14	Glaxosmithkline Spa	Novel method and compounds
US20040224986A1 (en)	2002-08-16	2004-11-11	Bart De Corte	Piperidinyl targeting compounds that selectively bind integrins
UA87854C2 (en)	2004-06-07	2009-08-25	Мерк Энд Ко., Инк.	N-(2-benzyl)-2-phenylbutanamides as androgen receptor modulators
ES2521679T3 (es)	2006-01-18	2014-11-13	Merck Patent Gmbh	Terapia específica usando ligandos de integrinas para el tratamiento del cáncer
US20100069302A1 (en)	2007-07-18	2010-03-18	Stefan Krueger	Specific therapy and medicament using integrin ligands for treating cancer
CN102448497A (zh)	2009-05-25	2012-05-09	默克专利有限公司	在癌症治疗中的西仑吉肽的持续给药
CA2950390C (fr)	2014-05-30	2020-09-22	Pfizer Inc.	Derives carbonitriles en tant que modulateurs selectifs du recepteur des androgenes
WO2023275715A1 (fr)	2021-06-30	2023-01-05	Pfizer Inc.	Métabolites de modulateurs sélectifs du récepteur des androgènes

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CH443281A (de) *	1964-02-18	1967-09-15	Hoffmann La Roche	Verfahren zur Herstellung von Dibenzocycloheptatrienverbindungen
US3335148A (en) *	1966-02-17	1967-08-08	Lilly Co Eli	9(3-pyridyl)derivative of fluorene, 9-fluorenol, xanthene, 9-xanthenol and the corresponding nonphytotoxic acid addition salts thereof
US5698551A (en) *	1995-04-07	1997-12-16	Novo Nordisk A/S	Heterocyclic compounds
PT910563E (pt) *	1995-06-29	2003-09-30	Smithkline Beecham Corp	Antagonistas de receptores de integrina
US5659033A (en) *	1995-09-13	1997-08-19	Neurogen Corporation	N-aminoalkylfluorenecarboxamides; a new class of dopamine receptor subtype specific ligands
JP2001501951A (ja) *	1996-10-07	2001-02-13	スミスクライン・ビーチャム・コーポレイション	骨形成刺激方法
CO4920232A1 (es) *	1997-01-08	2000-05-29	Smithkline Beecham Corp	Acidos aceticos dibenzo [a,d] cicloheptano con actividad antagonista del receptor de vitronectin

1998
- 1998-09-16 PE PE1998000881A patent/PE122699A1/es not_active Application Discontinuation
- 1998-09-16 AR ARP980104604A patent/AR015446A1/es not_active Application Discontinuation
- 1998-09-16 DZ DZ980219A patent/DZ2609A1/fr active
- 1998-09-18 WO PCT/US1998/019466 patent/WO1999015508A1/fr not_active Ceased
- 1998-09-18 PL PL98339381A patent/PL339381A1/xx unknown
- 1998-09-18 CN CN98810811A patent/CN1278250A/zh active Pending
- 1998-09-18 EA EA200000336A patent/EA200000336A1/ru unknown
- 1998-09-18 KR KR1020007002901A patent/KR20010024141A/ko not_active Ceased
- 1998-09-18 HU HU0003641A patent/HUP0003641A3/hu unknown
- 1998-09-18 AU AU93972/98A patent/AU738433B2/en not_active Ceased
- 1998-09-18 JP JP2000512816A patent/JP2001517658A/ja not_active Withdrawn
- 1998-09-18 ID IDW20000468A patent/ID24162A/id unknown
- 1998-09-18 AP APAP/P/2000/001766A patent/AP2000001766A0/en unknown
- 1998-09-18 NZ NZ503389A patent/NZ503389A/en not_active IP Right Cessation
- 1998-09-18 EP EP98947116A patent/EP1025090A4/fr not_active Withdrawn
- 1998-09-18 SK SK408-2000A patent/SK4082000A3/sk unknown
- 1998-09-18 CA CA002303487A patent/CA2303487A1/fr not_active Abandoned
- 1998-09-18 MA MA25266A patent/MA26547A1/fr unknown
- 1998-09-18 TR TR2000/00721T patent/TR200000721T2/xx unknown
- 1998-09-18 IL IL13502898A patent/IL135028A0/xx unknown
- 1998-09-18 BR BR9812340-8A patent/BR9812340A/pt not_active Application Discontinuation
- 1998-09-18 CO CO98053986A patent/CO5011087A1/es unknown
- 1998-09-23 TW TW087115535A patent/TW513303B/zh not_active IP Right Cessation
2000
- 2000-03-16 OA OA1200000079A patent/OA11341A/en unknown
- 2000-03-17 NO NO20001407A patent/NO20001407D0/no not_active Application Discontinuation
- 2000-04-07 BG BG104314A patent/BG104314A/xx unknown

Also Published As

Publication number	Publication date
HUP0003641A3 (en)	2002-10-28
CN1278250A (zh)	2000-12-27
EP1025090A4 (fr)	2000-11-08
AU738433B2 (en)	2001-09-20
EA200000336A1 (ru)	2000-10-30
NO20001407L (no)	2000-03-17
HUP0003641A2 (en)	2001-03-28
BG104314A (en)	2001-01-31
SK4082000A3 (en)	2000-09-12
WO1999015508A1 (fr)	1999-04-01
DZ2609A1 (fr)	2003-03-01
JP2001517658A (ja)	2001-10-09
TW513303B (en)	2002-12-11
CA2303487A1 (fr)	1999-04-01
OA11341A (en)	2003-12-10
NZ503389A (en)	2002-03-28
CO5011087A1 (es)	2001-02-28
NO20001407D0 (no)	2000-03-17
EP1025090A1 (fr)	2000-08-09
KR20010024141A (ko)	2001-03-26
MA26547A1 (fr)	2004-12-20
PE122699A1 (es)	2000-02-12
BR9812340A (pt)	2001-12-18
IL135028A0 (en)	2001-05-20
TR200000721T2 (tr)	2000-11-21
AR015446A1 (es)	2001-05-02
PL339381A1 (en)	2000-12-18
ID24162A (id)	2000-07-13
AU9397298A (en)	1999-04-12

Publication	Publication Date	Title
AP2000001766A0 (en)	1998-09-18	Vitronectin receptor anatagonists.
MX9805253A (es)	1998-10-31	Antagonistas del receptor de vitronectina.
MX9805255A (es)	1998-11-29	Antagonistas de receptor de vitronectina.
DE60218721D1 (en)	2007-04-19	Pyrimidinone als melanin concentrating hormone receptor 1
GB9514473D0 (en)	1995-09-13	Chemical compounds
MX9700041A (es)	1997-04-30	Antagonistas de receptor de vitronectina.
DE60112974D1 (en)	2005-09-29	Carbolinderivate
AU9393601A (en)	2002-04-15	Association of the cb1 receptor antagonist and a sibutramin, pharmaceutical compositions containing same and use thereof for treating obesity
TR200001012T2 (tr)	2000-09-21	Yeni ariloksi-alkil-dialkilaminler.
MXPA03002911A (es)	2003-09-10	Compuestos quimicos.
HU9600256D0 (en)	1996-03-28	Substituted diphenyl-sulfonamides, antagonists of endothelin
NO975975L (no)	1998-06-22	Vitronektinreseptor-antagonister, fremstilling samt anvendelse derav
NO20001514L (no)	2000-03-23	Vitronectin-reseptor-antagonist
NO20001515L (no)	2000-03-23	Vitronektin reseptor-antagonist
BG104038A (en)	2001-04-30	Use of specific antagonist of 5ht2 receptors for preparing medicines useful for treating sleep-disordered breathing
BG105651A (en)	2002-02-28	Vitronectin receptor antagonist
IL145645A0 (en)	2002-06-30	N-(2-phenyl-4-amino-butyl)-1-naphthamides as neurokinin-1 receptor antagonists
MXPA02012472A (es)	2004-01-26	Compuestos quimicos.
BR0108867A (pt)	2005-02-09	Antagonistas de receptor il-8
ITBO940427A0 (it)	1994-09-29	Articolazione d'anca per ortesi ortopedica.
MY133881A (en)	2007-11-30	"calcilytic compounds"
TWI255813B (en)	2006-06-01	Compounds for use as alphavbeta3 receptor antagonists
WO2000007544A3 (fr)	2000-05-18	Antagonistes du recepteur de la proteine s
NZ516209A (en)	2004-01-30	Indoloazepines as vasopressin receptor antagonists
DK1165184T3 (da)	2004-04-13	Estrogenreceptor-beta antagonisme og knoglesygdomme